Every Form 4 that EyePoint (EYPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EYPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EYPT filings page.
EyePoint, Inc. (EYPT) reported internal equity transfers by Chief Financial Officer George Elston on August 20, 2026. A total of 5,000 shares of common stock were shifted from an irrevocable family trust into Elston’s direct ownership, while 64,953 shares were transferred as a bona fide gift from his direct holdings into a grantor-retained annuity trust (GRAT) he serves as grantor, trustee and beneficiary. The family trust continues to hold 25,000 shares for the benefit of his children, and Elston disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. (EYPT) director Karen L. Zaderej reported an open-market or private purchase of 10,600 shares of Common Stock on 2026-08-18 at $4.93 per share. Following this transaction, she directly owns 49,100 shares of EyePoint, Inc. common stock. The Rule 10b5-1 trading plan checkbox was not marked, indicating the trade was not reported as made under such a plan.
EyePoint, Inc. President and CEO Jay S. Duker exercised 16,667 restricted stock units into common stock on July 10, 2026. No shares were sold; 8,059 shares were withheld by the issuer to satisfy tax obligations, leaving him with 9,594 shares held directly. A Family Trust for his children holds 177,431 shares, and he disclaims beneficial ownership of those trust holdings.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported an option exercise-and-sale transaction in company stock. On June 30, 2026, he exercised options to acquire 4,875 shares of common stock at an exercise price of $8.26 per share, then sold 2,438 shares at a weighted average price of $15.0172 and 2,437 shares at $15.00 in open-market sales. Following these trades, his directly held common stock position was 0 shares, while his stock option holdings increased to 78,001 options with an exercise price of $8.26 expiring on January 3, 2035. A related footnote explains that 25% of this option grant vests on January 3, 2026, with the remainder vesting monthly over the following three years.
EyePoint, Inc. Chief Financial Officer George Elston reported routine equity compensation activity involving common stock and restricted stock units. He exercised 7,500 restricted stock units into 7,500 shares of common stock. Of these, 3,627 shares were withheld by EyePoint to cover tax obligations, and no shares were sold in the market.
Following these transactions, Elston holds 91,691 shares of common stock directly. In addition, 30,000 shares of common stock are held indirectly through a family trust for the benefit of his children, for which he disclaims beneficial ownership.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro exercised stock options and sold the resulting shares in a same-day transaction. On April 17, 2026, he exercised options to acquire 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares at $15.00 per share in an open-market sale.
Following these transactions, he reported no common stock held directly, while 80,438 stock options remained outstanding with an expiration date in 2035.
EyePoint, Inc. President and CEO Jay S. Duker restructured his holdings by selling shares and stock options to a family trust. On March 23, 2026, he sold 76,766 shares of Common Stock and options over an additional 150,000 shares to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note of $2,398,220.93, reflecting the fair market value of the securities. After the transactions, he continued to hold some Common Stock and options directly, while the Family Trust held the transferred positions. The securities in the Family Trust are for the benefit of his children, his spouse serves as trustee, and he disclaims beneficial ownership of those trust-held securities.
EyePoint, Inc. reported an insider-related purchase involving a family trust associated with President and CEO Jay S. Duker. The trust bought 1,500 shares of common stock in an open-market transaction at $13.1492 per share.
After this trade, the family trust holds 100,665 shares of EyePoint common stock, while Duker directly owns 77,752 shares. The shares in the trust are for the benefit of his children, with his spouse serving as trustee, and Duker disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. Chief Financial Officer George Elston reported non-sale insider transactions involving company common stock. On March 2, 2026, he made bona fide gift transfers totaling 10,000 shares, with 5,000 shares from his directly held stock and 5,000 shares from stock reported as indirectly held.
Footnotes explain that some shares were transferred to an irrevocable family trust for the benefit of his immediate family, with JP Morgan Trust Company of Delaware as trustee. The filing states that he disclaims beneficial ownership of the securities held in the family trust.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported insider transactions involving stock options and common shares. On March 4, 2026, he exercised a stock option covering 2,438 shares of common stock at an exercise price of $8.2600 per share and reported acquiring the corresponding common shares. He then sold 2,438 shares of common stock in open-market transactions at a weighted average price of $17.8719 per share, with individual sale prices ranging from $17.22 to $18.45. A separate option grant is disclosed as vesting 25% on January 3, 2026, with the remainder vesting monthly over the following three years.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported a set of option-related transactions. On February 17, 2026, he exercised stock options and acquired 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares in an open-market transaction at $15.00 per share. Following these moves, he reported holding 85,313 stock options and no directly held common shares from this transaction. A disclosed option award vests 25% on January 3, 2026, with the remainder vesting monthly over the next three years.
On January 6, 2026, EyePoint, Inc. director Nancy Lurker acquired 75,133 shares of common stock at $0.00 per share upon the vesting and settlement of previously granted restricted stock units. These units were part of an award that vests in three equal annual installments beginning January 6, 2024.
Following this transaction, she directly owned 294,346 shares of EyePoint common stock. An additional 126,889 shares are held indirectly by a family trust for the benefit of her children, for which her spouse is trustee, and she disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. President and CEO Jay S. Duker, who also serves as a director, reported routine equity activity on January 6, 2026 related to previously granted restricted stock units. A block of 20,793 restricted stock units converted into the same number of shares of common stock at an exercise price of $0.00, reflecting vesting of his equity award. To cover taxes on this vesting, 10,054 shares of common stock were withheld by EyePoint at a price of $16.86, and the filing specifies that no shares were sold in the market. After these transactions, Duker directly held 77,752 shares of common stock, and an additional 99,165 shares were reported as indirectly held by a family trust for the benefit of his children, for which he disclaims beneficial ownership.
EyePoint, Inc.’s Chief Financial Officer, Elston George, reported equity compensation activity involving restricted stock units and common shares. On January 6, 2026, 15,285 restricted stock units converted into 15,285 shares of common stock at an exercise price of $0.00, increasing his directly held common shares before withholding to 96,339.
On the same date, 4,487 of those common shares were withheld by the issuer at $16.86 per share to satisfy tax withholding obligations, rather than being sold in the market, leaving 91,852 common shares held directly. An additional 25,000 common shares are reported as held indirectly in a family trust for the benefit of his children, with the trust company as trustee and George disclaiming beneficial ownership of those securities.
EyePoint, Inc. Chief Medical Officer Ribeiro Ramiro reported exercising stock options and selling company shares. On January 5, 2026, Ramiro exercised an option to buy 29,250 shares of common stock at $8.26 per share, increasing his directly held common stock to 42,544 shares. That same day, he reported selling 42,544 shares of common stock at a weighted average price of $17.0957 per share, leaving him with no directly held common stock after the transactions.
Ramiro continues to hold 87,750 stock options following the reported activity. According to the filing, the option vests with 25% on January 3, 2026, with the remaining portion vesting monthly over the next three years, and carries an expiration date of January 3, 2035. The weighted average sale price reflects multiple trades between $16.68 and $17.51.
EyePoint, Inc. Chief Financial Officer Elston George reported multiple equity compensation transactions and related share issuances and tax withholdings in early January 2026. On January 2, 2026, he received 63,000 restricted stock units and a stock option for 126,000 shares, both at an exercise or conversion price of $0.00, with the RSUs vesting in three annual installments beginning January 2, 2027 and the option vesting 25% on January 2, 2027 and the remainder monthly over three years. On January 3 and 5, 2026, previously granted RSUs vested and converted into a total of 34,667 shares of common stock, with 6,324 and 4,403 shares withheld at prices of $17.48 and $17.43 to satisfy tax obligations, and no shares sold into the market. Following these transactions, he directly held 81,054 shares of common stock and derivative awards, and an additional 25,000 shares are held indirectly by a family trust for his children, for which he disclaims beneficial ownership.
EyePoint, Inc. director Reginald J. Sanders reported a grant of stock options. On January 2, 2026, he received 40,000 stock options with an exercise price of $17.48 per share. These options become exercisable on January 2, 2027 and expire on January 2, 2036, and each option corresponds to one share of common stock. Following this grant, Sanders beneficially owns 40,000 derivative securities, held in direct ownership.
EyePoint, Inc. director Nancy Lurker reported equity awards and updated share holdings. On January 2, 2026, she was granted a stock option to buy 40,000 shares of common stock at $17.48, exercisable starting January 2, 2027 and expiring January 2, 2036. On January 5, 2026, 12,666 restricted stock units were converted into the same number of common shares at $0.00 per share, leaving her with 219,213 shares of common stock held directly and 12,667 restricted stock units outstanding. Separately, 126,889 shares of common stock are held indirectly through a family trust for her children, with her spouse as trustee, and she disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. director Duty Stuart reported a grant of stock options in a Form 4 filing. On January 2, 2026, Stuart received a stock option (right to buy) covering 40,000 shares of EyePoint common stock at a conversion or exercise price of $17.48 per share. The option is first exercisable on January 2, 2027 and is scheduled to expire on January 2, 2036. Following this grant, Stuart beneficially owned 40,000 derivative securities related to EyePoint common stock, held in direct ownership form.
EyePoint Pharmaceuticals (EYPT) reported an insider transaction by its Chief Medical Officer. On 11/11/2025, the officer sold 2,722 shares of common stock in open market transactions at a weighted average price of $11.61. The filing states these shares were originally acquired on January 31, 2025 under the company’s 2019 Employee Stock Purchase Plan. Following the sale, the filing lists 0.00 shares beneficially owned, reported as Direct (D) ownership.
EyePoint Pharmaceuticals (EYPT) Chief Financial Officer George Elston reported transfers of company common stock on September 19, 2025. The filing shows 20,000 shares were disposed of from Mr. Elston's direct holdings and the same number were recorded as held indirectly in an irrevocable family trust for the benefit of his children, with JP Morgan Trust Company of Delaware as trustee. After the reported transactions, Mr. Elston's direct beneficial ownership is reported as 62,114 shares and the Family Trust holds 20,000 shares. The filing also notes 1,266 shares were acquired on July 31, 2025 under EyePoint’s 2019 Employee Stock Purchase Plan. The reporting attorney-in-fact signed the form on September 22, 2025.